<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710824</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0355</org_study_id>
    <nct_id>NCT03710824</nct_id>
  </id_info>
  <brief_title>Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib</brief_title>
  <acronym>QUALIFY IPF</acronym>
  <official_title>Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic
      Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from
      10-12 reference centers across Greece.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Health Related Quality of Life (HRQoL) using SGRQ score</measure>
    <time_frame>upto 52 weeks</time_frame>
    <description>St. George's Respiratory Questionnaire (SGRQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of mean change from baseline of dyspnoea burden with modified Medical Research Council scale (mMRC) score</measure>
    <time_frame>upto 12 months</time_frame>
    <description>modified Medical Research Council scale (mMRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of mean change form baseline to the follow up period of cough burden with Cough-Visual Analogue scale (cough-VAS)</measure>
    <time_frame>upto 12 months</time_frame>
    <description>Cough-Visual Analogue scale (cough-VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adhered patients to nintedanib treatment with Simplified Medication Adherence Questionnaire (SMAQ)</measure>
    <time_frame>upto 52 weeks</time_frame>
    <description>adapted for the treatment of idiopathic pulmonary fibrosis (IPF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of mean change of anxiety in IPF patients treated with nintedanib from baseline to follow up period via Generalized Anxiety Disorder Screener (GAD-7) Questionnaire</measure>
    <time_frame>upto 52 weeks</time_frame>
    <description>Generalized Anxiety Disorder Screener (GAD-7) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that use LTOT</measure>
    <time_frame>upto 52 weeks</time_frame>
    <description>Long Term Oxygen Treatment (LTOT)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Subjects with Idiopathic Pulmonary Fibrosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>diagnosed IPF patients initiating treatment with nintedanib</description>
    <arm_group_label>Subjects with Idiopathic Pulmonary Fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed IPF patients initiating treatment with nintedanib according to their
        physician's clinical decision will be enrolled in this study. In details, patients will be
        eligible to enroll in the study if the fulfil all the inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥40 years of age.

          -  Patients that have signed Informed Consent Form.

          -  Treatment naive patients with an initial IPF diagnosis no more than 3 months prior to
             enrolment according to 2011 American Thoracic Society (ATS)/ European Respiratory
             Society (ERS)/ Japanese Respiratory Society (JRS)/Latin American Thoracic Association
             (ALAT) guidelines who are initiating treatment with nintedanib (as monotherapy for
             IPF) the latest on the enrollement day or have initiated treatment with nintedanib (as
             monotherapy for IPF) within the past 7 days prior to enrolment.

          -  Patients for whom the decision to prescribe therapy with nintedanib according to the
             locally approved product's Summary of Product Characteristics (SmPC) has already been
             taken prior to their enrolment in the study and is clearly separated from the
             physician's decision to include the patient in the current study.

          -  Patients that are able to read, understand and complete the study specific
             questionnaires.

        Exclusion Criteria:

          -  Treatment with nintedanib for more than 7 days prior to study enrolment.

          -  Patients receiving a combination therapy of nintedanib &amp; pirfenidone for IPF.

          -  Patients that meet any of the contraindications to the administration of the study
             drug nintedanib according to the approved SmPC.

          -  Prior treatment with pirfenidone or other treatment for IPF.

          -  Participation in an interventional study.

          -  Patients currently receive treatment with any investigational drug/device/intervention
             or have received any investigational product within 1 month or 5 half-lives of the
             investigational agent (whichever is longer) before the initiation of therapy with
             nintedanib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University General Hospital of Evros</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marios Froudarakis</last_name>
      <phone>+30 25513 52096</phone>
      <email>marfroud@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gen. Hosp. of Chest Diseases &quot;Sotiria&quot;, Univ. Resp. Med.</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demosthenes Bouros</last_name>
      <phone>+302107763559</phone>
      <email>debouros@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital Attikon</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyros Papiris</last_name>
      <phone>6932646673</phone>
      <email>papiris@otenet.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion, University Pulmonology Cl</name>
      <address>
        <city>Heraklion</city>
        <zip>71100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aikaterini Antoniou</last_name>
      <phone>+302810 371966</phone>
      <email>kat.mich.antoniou@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Kerkyra</name>
      <address>
        <city>Kerkyra</city>
        <zip>49100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilias Papanikolaou</last_name>
      <phone>+302661360694</phone>
      <email>icpapanikolaou@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Daniil</last_name>
      <phone>+302413502898</phone>
      <email>zdaniil@med.uth.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A Pulmonology Clinic &quot;G.Papanikolaou&quot; Hospital Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aikaterini Markopoulou</last_name>
      <phone>+302313307706</phone>
      <email>markopoulouk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;G. Papanikolaou&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Despoina Papakosta</last_name>
      <phone>+302313307179</phone>
      <email>depapako@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http://trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

